These results show that bulk CD8 T cell hyperfunction in mice with CCl4‐induced advanced liver disease associates with impaired anti‐tumour responses, weakened and delayed responses to anti‐PD‐1 and anti‐CTLA‐4 immunotherapy, and that this dysfunction may persist after fibrosis regression. Here, CD8A is linked to liver disorder.